Business Context and Reporting Period
Ocular Therapeutix, Inc. (OCUL), a Delaware corporation, filed this Form 8-K on December 15, 2020. The report details the entry into a material definitive agreement regarding an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 3,725,000 shares of common stock (Firm Shares).
- Public Offering Price: $21.50 per share.
- Price to Company: $20.21 per share (after underwriting discounts).
- Expected Net Proceeds: Approximately $74.8 million (after discounts, commissions, and estimated expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 558,750 additional shares (Option Shares).
- Expected Closing Date: December 18, 2020.
Material Changes
This filing represents a significant capital raise event. The company entered into an underwriting agreement with Jefferies LLC and Piper Sandler & Co. to sell shares directly to the public. This transaction is expected to materially increase the company's cash liquidity upon closing.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue forecasts, or management commentary on future operational performance. The primary risk noted is that the closing of the offering is subject to customary closing conditions. The transaction is being executed pursuant to an automatically effective shelf registration statement on Form S-3.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $74.8 million net proceeds.
- Confirm whether the underwriters exercised the 558,750 share over-allotment option.
- Review the attached press releases (Exhibits 99.1 and 99.2) for the stated use of proceeds.
- Check subsequent filings for the updated share count and dilution impact.